Pricing/Valuation | CRMD Message Board Posts


CRMD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  47549 of 48329  at  8/13/2022 8:02:41 PM  by

mrices1.1

The following message was updated on 8/13/2022 8:29:25 PM.

Pricing/Valuation

  
Up until CMS notes came out I think most were assuming around $19/vial price - although I'm not sure where that # came from - did CRMD provide earlier or was that from some analyst
 
In the call they confirmed NTAP In-Pateint wac pricing of $1,462.50 x 3 vials = $4,387.50/patient. (wac = wholesale acquisition cost)  While that is list price before sales discounts, rebates etc, it is still incredible!  A quick search of average wac to list price differential for major drug companies shows an average 50% reduction, depending on drug and channel... https://www.drugchannels.net/2021/04/gross-to-net-bubble-update-net-prices.html
 
If that 50% held for Defencath for hospitals, list would be $700/vial or $2100 per in-patient treatment.  Let's assume dialysis centers would pay a lot less due to volume discounts, so maybe a 75% discount vs wac or $365/vial for dialysis. 
 
CRMD has provided the following estimates in terms of potential market opportunity:
In Patient: 2.5M x 3 vials
Dialysis: 80 M  x 1 Vial
Oncology/TPN:  "several hundred million" vials
 
That's market potential so lower that by a lot to get to market penetration by channel.  Use whatever conservative assumptions you want.  Here's a start
In-Patient: 30% mkt = 750k patients x 3 vials x $700 = 1.6B
Dialysis: 25% mkt  = 20M visits x $365/vial (75% discount from wac) = $7.3B
Oncology/TPN: 25% @ $365 =  $22.8B
 
You'll see no matter how aggressive CRMD wants to be in discounting wac and no matter how low mkt penetration is, the  revenue potential is astounding.  Based on assumptions above and using 5x multiple of revenue, In-Patient alone could make CRMD an $8B company which translates to $195/share!  Ridiculous right?   So be more conservative in your assumptions - it doesn't matter.  Based on a wac of $1462.5, Defencath is a blockbuster drug.  No matter how much they discount, no matter what low penetration they achieve, the numbers are too good to believe.  
 
Analysts have done their own volume projections, but if they were using $19/vial those revenue estimates are out the window.  The big change from just a few weeks ago is the wac price of $1462 (vs $19) - that is way, way, way higher than I think anyone was assuming, and that may be why we are going to continue to see strong pps growth in the month ahead regardless of PUDFA date.
 
Pls check my math.  Am I missing something?
 
 
 
 
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 16  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
47550 Re: Pricing/Valuation hayfarmer 6 8/13/2022 9:50:03 PM
47551 Re: Pricing/Valuation HotAirBaffoon 11 8/14/2022 11:50:16 AM
47562 Re: Pricing/Valuation ChazCSP 13 8/15/2022 12:35:25 PM




Financial Market Data provided by
.
Loading...